Filter Your Search

  • ?
    Participants who either do not have cancer but are at high risk for developing the disease or have had cancer and are at high risk for developing a new cancer.
  • ?
    These trials look at ways to improve the quality of life of cancer patients, especially those who have side effects from cancer and its treatment. They find new ways to help people cope with pain, nutrition problems, infection, nausea and vomiting, sleep disorders, depression and other health problems.
  • open for enrollment

    3-Tesla MRI in Finding Tumors in Patients With Known or Suspected Prostate Cancer

    Eligibility:

    Inclusion Criteria:

    • Patients with known or suspected prostate disease based on clinical data will be included in the study; patients with intermediate to high grade prostate cancer (Gleason's score >= 7 and prostate-specific antigen [PSA] of > 10ng/dl) will be referred from the outpatient clinics after evaluation by the treating physicians
    • Written informed consent will be signed by the patients before the MRI based on the guidelines approved by the Ohio State University Institutional Review board
    • Patients must have an estimated glomerular filtration rate of >= 30 mL/min/1.73m^2 within six weeks of the MRI to be included in the study

    Exclusion Criteria:

    • Patients with any type of bioimplant activated by mechanical, electronic, or magnetic means (e.g., cochlear implants, pacemakers, neurostimulators, biostimulators, electronic infusion pumps, etc.)
    • Patients with any type of ferromagnetic bioimplant that could potentially be displaced or damaged
    • Patients that have vascular or aneurysm clips, or metallic staples from a surgical procedure
    • Patients with permanent tattoo eye liner (may contain metallic coloring)
    • Patients that may have shrapnel imbedded in their bodies, such as from war wounds, metal workers and machinists (metallic fragments in or near eyes), severe auto accident victims
    • Patients that exhibit noticeable anxiety and/or claustrophobia
    • Patients who cannot adhere to the experimental protocols for any reason, or have an inability to communicate with the researcher
    • Patients who have cardiac or known circulatory impairment, and/or the inability to perspire (poor thermoregulatory function)
    • Patients with an estimated glomerular filtration rate of < 30 mL/min/1.73m^2 within six weeks of the MRI
    • Acute or chronic severe renal insufficiency (estimated glomerular filtration rate < 30 mL/min/1.73m^2)
    • Acute renal dysfunction due to the hepato-renal syndrome or in the perioperative liver transplantation period

    Principal Investigator: Michael V Knopp, MD, PhD

    Learn More
  • open for enrollment

    3 Tesla MRI in Patients With Bladder Cancer

    Eligibility:

    Inclusion Criteria:

    • Known bladder cancer
    • Scheduled for radical cystectomy and lymph node dissection.
    • Able and willing to give valid written informed consent.
    • No contraindications to the MRI(magnetic resonance imaging).

    Exclusion Criteria:

    • Not pregnant, planning to become pregnant during the study, or nursing.
    • No allergy to contrast agents.
    • Patient with significant renal insufficiency, i.e. an estimated glomerular filtration rate(eGRF) less than 30 mL/min/1.73m2.
    • Any condition conflict based on the investigation's clinical judgment that would prevent the patient from completion all trial assessments and visits.
    • Inability or unwillingness to cooperate with requirements of this trial.
    • Patients who exhibit noticeable anxiety and/or claustrophobia or who exhibit severe vertigo when they are moved into the MR.
    • Patients with sickle cell anemia and other hemolytic anemia.

    Principal Investigator: Michael V Knopp, MD, PhD

    Learn More
  • open for enrollment

    Communication & Peer Support Effects on Physical Activity in Overweight Postmenopausal Women

    Eligibility:

    Inclusion Criteria: - Present a letter/documentation from a primary physician stating that they can participate in a physical activity program that will require walking up to 10,000 steps per day - Have a body mass index (BMI) between 25 and 40 kg/m^2 (inclusive) - Be postmenopausal, defined as no period for 12 months if over age 55, or no period for 12 months; also, women who have had their ovaries removed will be considered as postmenopausal - Willing to participate in a wellness program that lasts 12 weeks and involves walking for at least 30 minutes a day on most days - Has access to a cell phone during the 12-week intervention - Functional knowledge of English (ability to both read and write) Exclusion Criteria: - Taking hormone replacement therapy within 3 months of enrollment - Taking Tamoxifen or Raloxifene within 3 months of enrollment - Enrolled in a weight management program, such as Weight Watchers - Engaged in regular, planned walking of at least 30 minutes a day - Previous history of breast cancer - Premenopausal - Age > 75 years, to minimize co-morbidities - Cannot walk one mile

    Principal Investigator: Electra D Paskett, PhD

    Learn More
  • open for enrollment

    Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer

    Eligibility:

    Inclusion Criteria:

    • Patients enrolled after August 28, 2011 must be candidates for cytoreductive surgery and consent to have their surgical treatment determined by randomization
    • Patients must have histologic diagnosis of epithelial ovarian carcinoma, peritoneal primary or fallopian tube carcinoma, which is now recurrent
    • Patients with the following histologic epithelial cell types are eligible: serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, transitional cell carcinoma, malignant Brenner's tumor, or adenocarcinoma not otherwise specified (N.O.S.)
    • Patients must have had a complete response to front-line platinum-taxane therapy (at least three cycles)
    • A complete response to front-line chemotherapy must include: negative physical exam, negative pelvic exam and normalization of CA125, if elevated at baseline; although not required, any radiographic assessment of disease status (e.g. CT, magnetic resonance imaging [MRI], positron emission tomography [PET]/CT, etc) obtained following the completion of primary therapy should be considered negative for disease
    • All patients must have also had a treatment-free interval without clinical evidence of progressive disease of at least 6 months from completion of front-line chemotherapy (both platinum and taxane); front-line therapy may have included a biologic agent (i.e. bevacizumab)
    • Front-line treatment may include maintenance therapy following complete clinical or pathological response; however, maintenance cytotoxic chemotherapy must be discontinued for a minimum of 6 months prior to documentation of recurrent disease; patients receiving maintenance biological therapy or hormonal therapy are ELIGIBLE provided their recurrence is documented more than 6 months from primary cytotoxic chemotherapy completion (includes maintenance chemotherapy) AND a minimum 4 weeks has elapsed since their last infusion of biological therapy
    • Patients must have clinically evident recurrent disease for the purpose of this study
    • Measurable disease (Response Evaluation Criteria in Solid Tumors [RECIST]) is defined as at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded); each lesion must be more than or equal to 20 mm when measured by conventional techniques, MRI or CT, or more than or equal to 10 mm when measured by spiral CT
    • Absolute neutrophil count (ANC) greater than or equal to 1,500/mm^3, equivalent to Common Toxicity Criteria for Adverse Events version (v)3.0 (CTCAE) grade 1
    • Platelets greater than or equal to 100,000/mm^3 (CTCAE grade 0-1)
    • Creatinine (non-isotope dilution mass spectrometry [IDMS]) =< 1.5 x institutional upper limit normal (ULN), CTCAE grade 1
    • Total bilirubin =< 1.5 ULN (CTCAE grade 1)
    • Serum glutamic oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST) =< 2.5 times the upper limit of normal in the absence of liver metastasis; SGOT/AST < 5.0 times ULN in the presence of liver metastasis
    • Alkaline phosphatase =< 2.5 times the upper limit of normal in the absence of liver metastasis; alkaline phosphatase < 5.0 times ULN in the presence of liver metastasis
    • This criterion applies only to the patients enrolled before August 29, 2011 and those enrolled after this date electing to receive bevacizumab; patients must have a urine protein-to-creatinine ratio (UPCR) < 1.0 mg/dL
    • This eligibility criterion does not apply to patients enrolled after August 28, 2011; patients who are not candidates for surgical cytoreduction are eligible for the chemotherapy randomization; patients are not considered candidates for surgical cytoreduction if complete cytoreduction in the estimation of the investigator is impossible or a medical infirmity precludes exploration and debulking
    • Patients must have met the pre-entry requirements specified
    • Patients must have signed an approved informed consent and authorization permitting release of personal health information
    • Patients must have a Gynecologic Oncology Group (GOG) performance status of 0, 1, or 2

    Exclusion Criteria:

    • Patients who have received more than one previous regimen of chemotherapy (maintenance is not considered a second regimen)
    • Patients receiving concurrent immunotherapy, or radiotherapy
    • Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded
    • Patients whom have already undergone secondary cytoreduction for recurrent disease are excluded
    • Patients with a prior histologic diagnosis of borderline, low malignant potential (grade 0) epithelial carcinoma that was surgically resected and who subsequently developed an unrelated, new invasive epithelial ovarian or peritoneal primary cancer are eligible provided that they meet the criteria listed
    • Patients who require parenteral hydration or nutrition and have evidence of partial bowel obstruction or perforation
    • Patients who have received prior chemotherapy for any abdominal or pelvic tumor (other than ovarian, fallopian tube, and primary peritoneal) are excluded
    • Patients with synchronous primary endometrial cancer, or a past history of primary endometrial cancer, are excluded, unless all of the following conditions are met: stage not greater than I-B; no more than superficial myometrial invasion, without vascular or lymphatic invasion; no poorly differentiated subtypes, including papillary serous, clear cell or other International Federation of Gynecology and Obstetrics (FIGO) grade 3 lesions
    • Patients with uncontrolled infection
    • Patients with concurrent severe medical problems unrelated to the malignancy that would significantly limit full compliance with the study or expose the patient to extreme risk or decreased life expectancy
    • Patients with >= grade 2 peripheral neuropathy
    • Patients with a history of allergic reactions to carboplatin and/or paclitaxel or chemically similar compounds; patients with allergic (hypersensitivity) reactions to these chemotherapeutic agents are NOT excluded IF they were successfully retreated following a desensitization program or protocol
    • This criterion applies only to the patients enrolled before August 29, 2011 and those enrolled after this date electing to receive bevacizumab; patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies
    • Patients of childbearing potential, not practicing adequate contraception, patients who are pregnant or patients who are nursing are not eligible for this trial; bevacizumab should not be administered to nursing women
    • Patients with other invasive malignancies, with the exception of non-melanoma skin cancer, who had (or have) any evidence of the other cancer present within the last 5 years or whose previous cancer treatment contraindicates this protocol therapy
    • This criterion applies only to the patients enrolled before August 29, 2011 and those enrolled after this date electing to receive bevacizumab; patients with active bleeding or pathologic conditions that carry high risk of bleeding such as a known bleeding disorder, coagulopathy, or tumor involving major vessels
    • This criterion applies only to the patients enrolled before August 29, 2011 and those enrolled after this date electing to receive bevacizumab; patients with a history or evidence upon physical examination of central nervous system (CNS) disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases or a history of stroke within 5 years of the first date of treatment on this study
    • This criterion applies only to the patients enrolled before August 29, 2011 and those enrolled after this date electing to receive bevacizumab; patients with clinically significant cardiovascular disease; this includes:
    • Patients with significant cardiac conduction abnormalities, i.e. PR interval > 0.24 seconds (sec) or 2nd or 3rd degree atrioventricular (AV) block
    • Uncontrolled hypertension, defined as systolic > 150 mm Hg or diastolic > 90 mm Hg
    • Myocardial infarction, cardiac arrhythmia or unstable angina < 6 months prior to registration
    • New York Heart Association (NYHA) grade II or greater congestive heart failure
    • Serious cardiac arrhythmia requiring medication
    • Grade II or greater peripheral vascular disease (exception: episodes of ischemia < 24 hours [hrs] in duration, that are managed non-surgically and without permanent deficit)
    • History of cerebrovascular attack (CVA) within six months
    • This criterion applies only to the patients enrolled before August 29, 2011 and those enrolled after this date electing to receive bevacizumab; patients who have had a major surgical procedure, open biopsy, dental extractions or other dental surgery/procedure that results in an open wound, or significant traumatic injury within 28 days prior to the first date of treatment on this study, or anticipation of need for major surgical procedure during the course of the study; patients with placement of vascular access device or core biopsy within 7 days prior to the first date of treatment on this study
    • Patients undergoing pre-treatment secondary cytoreduction will undergo therapy with bevacizumab on cycle #2
    • Patients undergoing pre-treatment surgery for purposes other than cytoreduction may also participate provided they meet eligibility; patients randomized to arms containing bevacizumab must wait a minimum of 28 days since that procedure to begin protocol treatment; patients who undergo an uncomplicated port placement must wait a minimum of 7 days to begin protocol treatment

    Principal Investigator: David M O'Malley, MD

    Learn More
  • open for enrollment

    Testing Interventions to Motivate and Educate

    Eligibility:

    Inclusion Criteria: - Age 50 or older - No prior history of familial/hereditary cancer syndrome (e.g. hereditary non-polyposis colon cancer), polyps, or inflammatory bowel disease (e.g. Crohn's disease) - Have a current phone number - Have had 2 or more visits to the Family Practice or General Internal Medicine Clinics in the past 2 years - Have a current address in records and no definite plans to move within the next year - Be at average risk for colorectal cancer - Be in good health as judged by their primary care doctor - Not be over the age of 85 Exclusion Criteria: - Less than 50 years old - Greater than 85 years old - History of familial/hereditary cancer syndrome, polyps, or Crohn's disease - History of contraindications to colorectal cancer screening, such as congenital heart failure, renal failure, dementia

    Principal Investigator: Electra D Paskett, PhD

    Learn More
  • open for enrollment

    Direct Visual Fluorescence in Finding Oral Cancer in High-Risk Patients and Patients Undergoing Routine Dental Care

    Eligibility:

    Inclusion Criteria:

    • HIGH-RISK POPULATION:
    • 33 consecutive consenting patients presenting to The Ohio State University James Cancer Hospital Otolaryngology Department with a suspicious oral lesion or prior biopsy-confirmed epithelial dysplasia (mild, moderate, severe), carcinoma in situ (CIS), or squamous cell carcinoma (SCC) will be recruited; adult patients presenting for initial evaluation for treatment planning and/or presenting for follow-up appointments monitoring for recurrence will be eligible to participate
    • GENERAL POPULATION:
    • 250 consecutive consenting patients presenting to The Ohio State University College of Dentistry for routing dental care will be recruited; adult patients presenting to the screening clinic for initial oral evaluation will be eligible to participate
    Learn More
  • open for enrollment

    Ohio Patient Navigator Research Program

    Eligibility:

    Inclusion Criteria: - Over age 18 years - Be a regular patient of the primary care practice - Be able to give informed consent - Have had either an abnormal screening test, an abnormal diagnostic test, or an abnormal clinical finding leading to diagnostic testing for cervical, breast, or colorectal cancer, or a diagnosis of cervical, breast, or colorectal cancer - Speak and understand English, or Spanish. For those participants who do not speak and understand English they will only be enrolled/consented into the program if translation services are available. Exclusion Criteria: - Cognitively impaired - Prior history of cancer (except for nonmelanoma of the skin) - Living in a nursing home - Prior navigation

    Principal Investigator: Electra D Paskett, PhD

    Learn More
  • open for enrollment

    Three Different Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

    Eligibility:

    DISEASE CHARACTERISTICS:

    • Histologically or cytologically documented small cell lung cancer (SCLC)
    • Limited-stage disease
    • Disease restricted to one hemithorax with regional lymph node metastases, including ipsilateral hilar, ipsilateral and contralateral mediastinal, and ipsilateral supraclavicular lymph nodes
    • The following patients are not eligible:
    • Patients with disease involvement of the contralateral hilar or supraclavicular lymph nodes
    • Patients with pleural effusions that are visible on plain chest radiographs, whether cytologically positive or not
    • Patients with cytologically positive pleural or pericardial fluid, regardless of the appearance on plain x-ray
    • Measurable disease, defined as at least one unidimensionally measurable lesion = 2 cm by conventional techniques OR = 1 cm by spiral CT scan

    PATIENT CHARACTERISTICS:

    • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
    • Granulocytes = 1,500/µl
    • Platelet count = 100,000/µl
    • Total bilirubin = 1.5 times upper limit of normal (ULN)
    • AST = 2.0 times ULN
    • Serum creatinine = 1.5 times ULN OR creatinine clearance = 70 mL/min
    • Not pregnant or nursing
    • Negative pregnancy test
    • Fertile patients must use effective contraception

    PRIOR CONCURRENT THERAPY:

    • Patients may have received one and only one course of chemotherapy prior to enrolling on CALGB 30610, which must have included cisplatin and etoposide
    • If a patient has had one course of cisplatin/etoposide prior to registration, the patient must have had all of the prior-to-registration tests prior to starting their first course of chemotherapy
    • Registration to CALGB-30610 must take place within 14-21 days after the start of the non-protocol therapy; failing to do all of the above will make the patient NOT eligible for CALGB-30610
    • No prior radiotherapy or chemotherapy (except for the chemotherapy described above) for SCLC
    • No prior mediastinal or thoracic radiotherapy
    • No prior complete surgical resection of SCLC
    Learn More
  • open for enrollment

    A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment

    Eligibility:

    Inclusion Criteria:

    1. Histologically proven, metastatic or locally advanced non resectable, or recurrent post surgery GIST

    2. Naïve patient or patient previously treated with imatinib as neoadjuvant/adjuvant who relapsed after imatinib discontinuation

    3. C-Kit (CD117) positive tumours detected immuno-histochemically or PDGF positive if c-kit negative

    4. Man or woman, age >18 years

    5. Man and woman of childbearing potential, (entering the study after a menstrual period and who have a negative pregnancy test) must agree to use two methods (one for the patient and one for the partner) of medically acceptable forms of contraception during the study and for 3 months after the last treatment intake

    6. Patient able and willing to comply with study procedures as per protocol

    7. Patient able to understand, sign, and date the written voluntary informed consent form at screening visit prior to any protocol-specific procedures

    Exclusion Criteria:

    1. Patient previously treated by tyrosine kinase inhibitors except imatinib in case of inclusion criteria 2

    2. Patient treated for a cancer other than GIST within 5 years before enrolment, with the exception of basal cell carcinoma or cervical cancer in situ

    3. Patient with active central nervous system (CNS) metastasis or with history of CNS metastasis

    4. Patient with grade III/IV cardiac problems as defined by the New York Heart Association Criteria. (i.e. congestive heart failure, myocardial infarction within 6 months before baseline) Patient with any condition that the physician judges could be detrimental to subjects participating in this study; including any clinically important deviations from normal clinical laboratory values or concurrent medical events Previous treatment

    5. Treatment with any investigational agent within 4 weeks prior baseline

    6. Treatment by imatinib as neoadjuvant/adjuvant therapy within 4 weeks prior baseline

    Principal Investigator: Tanios Bekaii-Saab, MD

    Learn More
  • open for enrollment

    Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

    Eligibility:

    DISEASE CHARACTERISTICS:

    • Adenocarcinoma of the prostate treated primarily with radical prostatectomy
    • Pathologically proven to be lymph node-negative by pelvic lymphadenectomy (N0) or lymph node status pathologically unknown (Nx [undissected pelvic lymph nodes because lymph node dissection is not required])
    • Any type of radical prostatectomy allowed, including retropubic, perineal, laparoscopic, or robotically assisted
    • Meets 1 of the following pathologic classifications:
    • T3 N0/Nx disease with or without positive prostatectomy margins
    • T2 N0/Nx disease with or without positive prostatectomy margins
    • N1 patients are ineligible, as are those with pelvic lymph node enlargement = 1.5 cm in greatest dimension by CT scan or MRI of the pelvis, unless the enlarged lymph node is negative
    • Prostatectomy Gleason score of 9 or less
    • A post-radical prostatectomy entry PSA of = 0.1 and = 1.0 ng/mL at least 6 weeks after prostatectomy and within 30 days of registration
    • Serum total testosterone = 40% of the lower limit of normal (patients who have had a unilateral orchiectomy are eligible as long as this requirement is met)
    • No distant metastases based on history/physical examination, CT scan or MRI of the abdomen and pelvis, and bone scan
    • No palpable prostatic fossa abnormality/mass suggestive of recurrence, unless shown by biopsy under ultrasound guidance not to contain cancer

    PATIENT CHARACTERISTICS:

    • Zubrod performance status 0-1
    • Platelets = 100,000/mm^3
    • Hemoglobin = 10.0 g/dL (the use of transfusion or other intervention to achieve this is allowed)
    • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2 x upper limit of normal
    • No prior invasive malignancy (except nonmelanoma skin cancer) or superficial bladder cancer unless disease free for a minimum of 5 years (e.g., carcinoma in situ of the oral cavity is permissible)
    • No severe, active co-morbidity, including any of the following:
    • History of inflammatory bowel disease
    • History of hepatitis B or C
    • Unstable angina and/or congestive heart failure requiring hospitalization within the past 6 months
    • Transmural myocardial infarction within the past 6 months
    • Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
    • Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
    • Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects
    • Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control (CDC) definition
    • HIV testing is not required for entry
    • No prior allergic reaction to the study drug(s) involved in this protocol

    PRIOR CONCURRENT THERAPY:

    • See Disease Characteristics
    • More than 5 years since prior chemotherapy for any other disease site
    • No androgen-deprivation therapy started prior to prostatectomy for > 6 months duration
    • The use of finasteride or dutasteride (± tamsulosin) for longer periods prior to prostatectomy is acceptable
    • No androgen-deprivation therapy started after prostatectomy and prior to registration
    • The use of finasteride or dutasteride (± tamsulosin) after prostatectomy is not acceptable, it must be stopped within 3 months after prostatectomy
    • No neoadjuvant chemotherapy before or after prostatectomy
    • No prior cryosurgery or brachytherapy of the prostate (prostatectomy should be the primary treatment and not a salvage procedure)
    • No prior pelvic radiotherapy
    Learn More